Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis

David A Russler-Germain; Edward R Scheffer Cliff; Nancy L Bartlett

doi:10.1182/blood.2023022048

Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis

Blood. 2023 Dec 21;142(25):2216-2219. doi: 10.1182/blood.2023022048.

Authors

David A Russler-Germain^{1

2}, Edward R Scheffer Cliff^{3

4}, Nancy L Bartlett^{1

2}

Affiliations

¹ Division of Oncology, Washington University School of Medicine, St. Louis, MO.
² Siteman Cancer Center, St. Louis, MO.
³ Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
⁴ Harvard Medical School, Boston, MA.

PMID: 37797275
DOI: 10.1182/blood.2023022048

Abstract

Subgroup analysis from the POLARIX trial of polatuzumab vedotin plus chemotherapy for untreated large B-cell lymphoma suggests greater efficacy among patients with activated B-cell subtype disease. Both preclinical and additional clinical evidence support this interaction between cell-of-origin and polatuzumab efficacy.

MeSH terms

Antibodies, Monoclonal / adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Humans
Immunoconjugates* / adverse effects
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Rituximab / therapeutic use

Substances

polatuzumab vedotin
Antibodies, Monoclonal
Immunoconjugates
Rituximab